Prevalence and impact of antipsychotic discontinuation among commercially-insured patients with bipolar disorder.
Rezaul KhandkerFarid ChekaniBrendan LimoneEllen RiehlePublished in: Journal of medical economics (2023)
Most patients with bipolar mania or mixed states discontinue antipsychotic treatment in less than 2 years. Antipsychotic discontinuation contributes to excess healthcare costs. Future research focusing on the reasons for discontinuation and tailoring disease management based on comorbidities may inform adherence improvement initiatives.